Search results
Showing 1 to 8 of 8 results for ceftazidime with avibactam
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....
View recommendations for HTE1Show all sections
Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)
This guideline sets out an antimicrobial prescribing strategy for hospital-acquired pneumonia. It does not cover ventilator-associated pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.
A new model for evaluating and purchasing antimicrobials in the UK
NICE published guidance on the 2 products selected for the pilot: ceftazidime with avibactam and cefiderocol , in April 2022. This...
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.